Centessa Pharmaceuticals (CNTA) Amortization - Intangibles (2020)

Centessa Pharmaceuticals (CNTA) reported Amortization - Intangibles of $90000.0 for Q4 2020, up 15.38% quarter-over-quarter from $78000.0 in Q3 2020.

Centessa Pharmaceuticals (CNTA) Amortization - Intangibles (2020) Analysis & Trends

Centessa Pharmaceuticals (CNTA) has 1 years of Amortization - Intangibles data on file, last reported at $90000.0 in Q4 2020.

Amortization - Intangibles for Q4 2020 came in at $90000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2021 was $90000.0 (changed N/A YoY), and the FY2020 annual result was $310000.0, up 162.71% from the prior year.
Amortization - Intangibles advanced to $90000.0 in Q4 2020 per CNTA's latest filing, from $78000.0 in the prior quarter.
Over five years, Amortization - Intangibles peaked at $90000.0 in Q4 2020 and troughed at $72000.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Centessa Pharmaceuticals	6.15 Bn	6.15 Bn	-

Download Data